Clinical Trials for Acute Myeloid Leukemia
301 acute myeloid leukemia trials indexed, 158 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a type of cancer that starts in the bone marrow, where blood cells are made. It affects myeloid cells, which normally develop into red blood cells, white blood cells, or platelets. In AML, these immature cells, called myeloblasts, grow uncontrollably and do not mature properly. This buildup of abnormal cells interferes with the production of healthy blood cells. Doctors diagnose AML through blood tests and bone marrow biopsies, which help identify the presence of these immature cells and genetic changes linked to the disease.
Common symptoms of AML include fatigue, frequent infections, easy bruising or bleeding, and shortness of breath. These symptoms result from low levels of normal blood cells. AML can develop at any age but is most common in adults over 60 years old. Men are slightly more likely to develop AML than women. Risk factors include previous chemotherapy or radiation therapy, exposure to certain chemicals like benzene, smoking, and some genetic disorders. However, many patients have no known risk factors when diagnosed.
AML is a serious medical condition with significant health impacts. It accounts for about 1.2% of all new cancer cases in the United States but has a high mortality rate. The five-year survival rate for AML is approximately 30%, which is lower than many other cancers. This disease also carries a substantial economic burden due to intensive treatment and hospital stays. Early diagnosis and treatment are critical to improving outcomes for patients with AML.
The Acute Myeloid Leukemia Treatment Landscape
The first-line treatment for AML often involves intensive chemotherapy aimed at inducing remission. The standard approach includes a combination of cytarabine and an anthracycline drug. This initial phase, called induction therapy, is followed by consolidation therapy to eliminate any remaining leukemia cells. For some patients, especially younger ones or those with high-risk disease, a stem cell transplant may be recommended after chemotherapy. Treatment plans are tailored based on patient age, overall health, and specific genetic mutations found in the leukemia cells.
When first-line treatments fail or the disease returns, second- and third-line options come into play. These may include targeted therapies such as FLT3 inhibitors, IDH inhibitors, and hypomethylating agents. Drug classes like kinase inhibitors and BCL-2 inhibitors are also used in certain cases. Examples of established drugs in these categories include midostaurin for FLT3 mutations and venetoclax for BCL-2 inhibition. Clinical decisions depend on previous treatments, mutation status, and patient tolerance.
Despite available therapies, many patients face challenges such as drug resistance, relapse, and severe side effects. Older adults and those with certain genetic profiles often respond poorly to standard treatments. Side effects like infections, organ toxicity, and prolonged hospitalization are common. Research is focused on developing therapies that improve survival while reducing toxicity. New approaches include immunotherapies and combination treatments designed to overcome resistance and target leukemia cells more precisely.
Why Clinical Trials Matter for Acute Myeloid Leukemia
Clinical trials offer patients with AML access to new treatments that are not yet widely available. These trials may provide options for those who have not responded well to standard therapies. According to ClinicalTrials.gov, there are currently 301 acute myeloid leukemia clinical trials indexed, with 158 actively recruiting participants. Being part of a trial also means closer monitoring by medical teams, which can help manage side effects and complications. Additionally, patient participation contributes to scientific knowledge that can improve future AML care.
Joining a clinical trial involves certain risks. New treatments may not work as expected or could have unknown side effects. Some trials include placebo groups, meaning not all participants receive the experimental therapy. Additional clinic visits and tests are often required, which can be time-consuming and tiring. Patients and caregivers should carefully discuss potential benefits and risks with their healthcare providers before enrolling in any trial.
The landscape of AML clinical trials includes studies sponsored by academic institutions, pharmaceutical companies, and cooperative research groups. These diverse sponsors help explore a wide range of treatment strategies. ClinicalTrials.gov serves as a central registry where patients and doctors can find detailed information about ongoing and upcoming trials. This resource helps connect eligible participants with studies that match their specific disease characteristics and treatment needs.
What to Look for in a Acute Myeloid Leukemia Clinical Trial
Clinical trials for Acute Myeloid Leukemia (AML) are divided into four phases. Phase 1 trials test the safety of a new treatment and find the right dose. Phase 2 trials focus on how well the treatment works and further assess safety. Phase 3 trials compare the new treatment to the current standard to see if it offers any benefits. Phase 4 trials happen after a treatment is approved to monitor long-term effects. In AML, most trials are Phase 1, with 139 studies. Phase 2 has 91 trials, Phase 3 has 20, and 18 trials have no phase specified. This shows many early-stage studies aim to find safe and effective treatments for AML.
Inclusion criteria help decide who can join a trial. For AML, age limits often range from 18 to 75 years, but some trials may accept younger or older patients. Prior treatments are important: some trials require patients to have tried specific therapies or be newly diagnosed. Biomarkers, like genetic mutations or cell markers, can also be key to eligibility. Trials may focus on certain AML subtypes or disease stages. The length of the disease, such as newly diagnosed versus relapsed AML, can affect eligibility. These criteria ensure the treatment is tested on the right group of patients for the study’s goals.
Exclusion criteria prevent patients from joining if there are risks or factors that could interfere with the study. Common reasons include other serious health conditions like heart or liver disease, which could increase side effects. Drug interactions are a concern if patients take medicines that affect the trial drug’s safety or effectiveness. Safety thresholds, such as low blood counts or poor organ function, may exclude patients to avoid harm. These criteria protect patients and help keep the study results clear and reliable.
Patients should consider practical aspects before joining a trial. The length of the study can range from a few months to several years. Visit schedules vary and may include frequent hospital trips for tests and treatments. Travel to the trial site can be challenging, especially if it is far from home. Patients should ask the research team key questions: What are the main risks and side effects? How often will I need to visit the clinic? What happens if I want to leave the trial early? Are there costs not covered by the study? Understanding these details helps patients make informed decisions about participating.
Primary Sources and Further Reading
For those interested in learning more about Acute Myeloid Leukemia and clinical trials, trusted sources provide detailed and up-to-date information. These resources cover treatment options, clinical trial basics, and patient support. Exploring these websites can help patients and caregivers better understand the disease and available research opportunities.
- National Cancer Institute: Adult Acute Myeloid Leukemia Treatment
- MedlinePlus: Leukemia
- ClinicalTrials.gov: Acute Myeloid Leukemia Trials
- National Heart, Lung, and Blood Institute: Acute Myeloid Leukemia
Latest Research and Emerging Treatments for Acute Myeloid Leukemia (2026)
Current acute myeloid leukemia treatment research includes several Phase 3 trials testing new drugs and combinations. One study is evaluating ziftomenib combined with venetoclax and azacitidine or traditional chemotherapy drugs like daunorubicin and cytarabine. Ziftomenib targets specific genetic mutations found in some AML patients, such as NPM1 or KMT2A rearrangements. By focusing on these mutations, the drug aims to improve remission rates and survival for patients who have not received prior treatment (NCT07007312).
Another trial is testing revumenib with intensive chemotherapy in adults newly diagnosed with AML who have an NPM1 mutation (NCT07211958). Revumenib is designed to interfere with a molecular pathway involved in cancer cell growth. Early data suggests combining this drug with standard chemotherapy could provide better outcomes compared to chemotherapy alone. For patients, this might mean more effective treatment options that specifically address the biology of their leukemia.
Research also includes mocravimod as an additional and maintenance therapy for AML patients undergoing allogeneic stem cell transplant (NCT05429632). Mocravimod may help reduce the risk of relapse after transplant by modulating the immune system. Other studies are testing venetoclax in combination with chemotherapy to improve event-free survival and reduce side effects (NCT04628026). These new drugs for acute myeloid leukemia could offer patients treatments tailored to their condition, potentially improving quality of life and long-term outcomes in 2026 and beyond.
Frequently asked questions about Acute Myeloid Leukemia trials
How do I find Acute Myeloid Leukemia clinical trials?
The authoritative source for Acute Myeloid Leukemia clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 301 acute myeloid leukemia studies are currently indexed. You can search by entering "acute myeloid leukemia" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new acute myeloid leukemia trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Acute Myeloid Leukemia trials in?
Across the 301 acute myeloid leukemia trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Acute Myeloid Leukemia clinical trials are currently recruiting?
As of the latest scan, 158 acute myeloid leukemia trials have a "Recruiting" status on ClinicalTrials.gov, out of 301 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting acute myeloid leukemia trial matches their tracked condition.
Stay informed about acute myeloid leukemia research
Get a weekly briefing with the trials that matter most.